Loxo Oncology announces publication of larotrectinib clinical data in the NEJM
Loxo Oncology announced a publication in the New England Journal of Medicine for larotrectinib in treatment of pediatric and adult patients whose tumors harbor tropomyosin receptor kinase gene fusions. It includes the first 55 enrolled adult and pediatric patients with TRK fusion cancers. February 21, 2018